Table 1.
Selected characteristics of study subjects
| Discovery stage (N = 341) | Replication stage (N = 206) | Combined stage (N = 547) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients (%) | No. of Death (%) | MST (months) | P a | No. of Patients (%) | No. of Death (%) | MST (months) | P a | No. of Patients (%) | No.of Death (%) | MST (months) | P a | |
| Age at diagnosis | 0.4360 | 0.3489 | 0.3718 | |||||||||
| ≤60 | 153 (44.87) | 136 (88.89) | 7.4 | 93 (45.1) | 67 (72.0) | 9.2 | 335 (61.2) | 279 (83.3) | 8.2 | |||
| >60 | 188 (55.13) | 176 (93.62) | 7.2 | 113 (54.9) | 88 (77.9) | 8.3 | 212 (38.8) | 188 (88.7) | 7.6 | |||
| Gender | 0.3208 | 0.9921 | 0.1731 | |||||||||
| Male | 202 (59.24) | 180 (89.11) | 7.4 | 133 (64.6) | 99 (74.4) | 8.6 | 246 (45.0) | 203 (82.5) | 7.9 | |||
| Female | 139 (40.76) | 132 (94.96) | 7.2 | 73 (35.4) | 56 (76.7) | 9.8 | 301 (55.0) | 264 (87.7) | 7.8 | |||
| Smoking status | 0.5021 | 0.4905 | 0.3473 | |||||||||
| Yes | 74 (21.70) | 68 (91.89) | 6.9 | 52 (25.2) | 43 (82.7) | 8.6 | 421 (77.0) | 356 (84.6) | 7.3 | |||
| No | 267 (78.30) | 244 (91.39) | 7.6 | 154 (74.8) | 112 (72.7) | 8.9 | 126 (23.0) | 111 (88.1) | 8.0 | |||
| Drinking status | 0.9305 | 0.9296 | 0.9963 | |||||||||
| Yes | 62 (18.18) | 56 (90.32) | 6.8 | 38 (18.4) | 30 (78.9) | 10.3 | 447 (81.7) | 381 (85.2) | 8.1 | |||
| No | 279 (81.82) | 256 (91.76) | 7.4 | 168 (81.6) | 125 (74.4) | 8.5 | 100 (18.3) | 86 (86.0) | 7.8 | |||
| Clinical stage | 1.98E‐08 | 3.37E‐15 | 9.56E‐21 | |||||||||
| Local | 72 (21.11) | 61 (84.72) | 9.3 | 54 (26.2) | 29 (53.7) | 18.8 | 126 (23.0) | 90 (71.4) | 13.9 | |||
| Locally advanced | 151 (44.28) | 133 (88.08) | 8.9 | 87 (42.2) | 70 (80.5) | 9.2 | 238 (43.5) | 203 (85.3) | 9.1 | |||
| Metastatic | 118 (34.60) | 118 (100.00) | 5.1 | 65 (31.6) | 56 (86.2) | 4.2 | 183 (33.5) | 174 (95.1) | 4.8 | |||
Abbreviation: MST, median survival time.
a
Calculated using the log‐rank test.